Skip to main content
News

Actelion obtains an option to in-license vamorolone from ReveraGen

By November 7, 2016No Comments

Vamorolone, a novel compound for the treatment of Duchenne Muscular Dystrophy, holds potential to better preserve muscle function and prolong ambulation for the patient, without some of the side effects associated with glucocorticoid therapy.  

ALLSCHWIL, SWITZERLAND, and ROCKVILLE (MD), USA – 03 November 2016 – Actelion Ltd (SIX: ATLN) and ReveraGen BioPharma, Inc., a privately held company engaged in the discovery and development of proprietary therapeutic products for neuromuscular and inflammatory diseases, announced today that they have entered into an agreement. By this agreement, Actelion has obtained an exclusive option to in-license ReveraGen’s lead compound vamorolone for the treatment of Duchenne Muscular Dystrophy at two different stages in its development.

{iframe}http://globenewswire.com/news-release/2016/11/03/886054/0/en/Actelion-obtains-an-option-to-in-license-vamorolone-from-ReveraGen.html{/iframe}

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.